A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004).

Autor: Zhou C; Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai 200433, China. Electronic address: caicunzhoudr@163.com., Hu Y; Department of Medical Oncology, Hubei Cancer Hospital, Wuhan 430000, China., Arkania E; LTD Israeli-Georgian Medical Research Clinic 'Helsicore', Tbilisi 0112, Georgia., Kilickap S; Department of Medical Oncology, Hacettepe University Faculty of Medicine, Ankara 06230, Turkey., Ying K; Department of Pneumology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, China., Xu F; Department of Pneumology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China., Wu L; Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China., Wang X; Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou 221009, China., Viguro M; Clinical Research Department, Medical Center 'Mriya Med-Service', Kryvyi Rih 50000, Ukraine., Makharadze T; LTD 'High Technology Hospital MedCenter', Batumi 6010, Georgia., Sun H; Department of Medical Oncology, Jiamusi Cancer Hospital, Jiamusi 154007, China., Luo F; Lung Cancer Center, West China Hospital of Sichuan University, Chengdu 610041, China., Shi J; Department of Medical Oncology, Linyi Cancer Hospital, Linyi 276000, China., Zang A; Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding 071000, China., Pan Y; Department of Medical Oncology, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China., Chen Z; Department of Medical Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei 230601, China., Jia Z; Department of Oncology, Linyi People's Hospital, Linyi 276002, China., Kuchava V; LTD Institute of Clinical Oncology, Tbilisi 0159, Georgia., Lu P; Department of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China., Zhang L; Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China., Cheng Y; Department of Oncology, Jilin Cancer Hospital, Changchun 130012, China., Kang W; Shanghai Henlius Biotech, Inc., Shanghai 200233, China., Wang Q; Shanghai Henlius Biotech, Inc., Shanghai 200233, China., Yu H; Shanghai Henlius Biotech, Inc., Shanghai 200233, China., Li J; Shanghai Henlius Biotech, Inc., Shanghai 200233, China., Zhu J; Shanghai Henlius Biotech, Inc., Shanghai 200233, China.

Publikováno v: Cancer cell [Cancer Cell] 2024 Feb 12; Vol. 42 (2), pp. 198-208.e3. Date of Electronic Publication: 2024 Jan 04.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

OA09.05 A Phase 3 Study of Serplulimab Plus Chemotherapy as First-Line Treatment for Squamous Non-small-Cell Lung Cancer (ASTRUM-004).

Autor: Zhou, C., Hu, Y., Arkania, E., Kilickap, S., Ying, K., Xu, F., Wu, L., Wang, X., Viguro, M., Makharadze, T., Sun, H., Luo, F., Shi, J., Zang, A., Pan, Y., Chen, Z., Jia, Z., Kuchava, V., Lu, P., Zhang, L.

Publikováno v: Journal of Thoracic Oncology; 2023 Supplement, Vol. 18 Issue 11, pS63-S64, 2p

LBA9 Updated results of first-line serplulimab versus placebo combined with chemotherapy in extensive-stage small cell lung cancer: An international multicentre phase III study (ASTRUM-005).

Autor: Cheng, Y.¹ (AUTHOR), Han, L.² (AUTHOR), Wu, L.³ (AUTHOR), Chen, J.⁴ (AUTHOR), Sun, H.⁵ (AUTHOR), Wen, G.⁶ (AUTHOR), Ji, Y.⁷ (AUTHOR), Dvorkin, M.⁸ (AUTHOR), Shi, J.^9,10 (AUTHOR), Pan, Z.¹¹ (AUTHOR), Wang, X.¹² (AUTHOR), Bai, Y.¹³ (AUTHOR), Melkadze, T.¹⁴ (AUTHOR), Pan, Y.¹⁵ (AUTHOR), Min, X.¹⁶ (AUTHOR), Viguro, M.¹⁷ (AUTHOR), Kang, W.¹⁸ (AUTHOR), Wang, Q.¹⁸ (AUTHOR), Zhu, J.¹⁹ (AUTHOR)

Publikováno v: Annals of Oncology. Nov2022 Suppl 9, Vol. 33, pS1562-S1562. 1p.